Vol. 12 No. 1 (2025): January-December 2025

Published: 2025-12-31

Full Issue

Vol. 12, January-December 2025

Editorial (on invitation only)

Spending caps for pharmaceuticals within the pharmaceutical policies framework: critical issues and reform options

Claudio Jommi

214-217

DOI: https://doi.org/10.33393/grhta.2025.3622
- PDF
- ePub

Review

Estimation of patients potentially eligible for icosapent ethyl therapy in Italy through a review of literature data

Pasquale Perrone Filardi, Emanuela Arcangeli, Pierluigi Carullo, Carlotta Galeone, Marcello Arca

234-241

DOI: https://doi.org/10.33393/grhta.2025.3503
- ePub
- PDF

Point of View

Therapeutic evolution: translating pharmacological innovation in tangible benefit for people with hemophilia A. A multistakeholder perspective

Matteo Nicola Dario Di Minno, Valentina Drago, Andrea Marcellusi, Salvatore Amato, Consalvo Mattia, Enrico Ferri Grazzi, Filippo Drago, Diego Fornasari

256-264

DOI: https://doi.org/10.33393/grhta.2025.3618
- ePub
- PDF
Patient and public involvement in health technology assessment committees: who is free from conflicts of interest?

Gustavo H Marin, Santiago Hasdeu

242-244

DOI: https://doi.org/10.33393/grhta.2025.3623
- PDF
- ePub
Paving the road for a successful EU HTA Reform implementation

Hans Severens, Andrew Dillon, Francois Meyer, Claudio Jommi, Iga Lipska, Pier-Luigi Canonico, Oriol Solà-Morales, Herbert Altmann

194-197

DOI: https://doi.org/10.33393/grhta.2025.3502
- PDF
- ePub
Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals

Valentina Drago, Tiziana Mele, Francesca Patarnello, Francesca Randon, Cristina Teruzzi, Filippo Drago

43-48

DOI: https://doi.org/10.33393/grhta.2025.3469
- PDF
- ePub
- HTML
Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices

Michela Bobini, Eugenio Di Brino, Americo Cicchetti

29-33

DOI: https://doi.org/10.33393/grhta.2025.3399
- PDF
- ePub
- HTML
What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe

Iga Lipska, Francois Meyer, Pier-Luigi Canonico, Herbert Altmann, Oriol Solà-Morales

7-8

DOI: https://doi.org/10.33393/grhta.2025.3354
- PDF
- ePub

Original Research Articles

Clinical and economic burden of urinary tract infections in patients with spinal cord injury and multiple sclerosis in Italy

Filippo Rumi, Agostino Fortunato, Eugenio Di Brino, Michele Basile, Debora Antonini, Luisa De Palma, Giulio Del Popolo, Gruppo GSC

249-255

DOI: https://doi.org/10.33393/grhta.2025.3607
- ePub
- PDF
Planning and allocating resources for pharmaceuticals to health care organisations: a proposal from the Regional Pharmaceutical Policies Forum

Claudio Jommi, Barbara Rebesco, Francesco Perrone, Rosy Amodeo, Alberto Bortolami

265-270

DOI: https://doi.org/10.33393/grhta.2025.3598
- PDF
- ePub
From Regulatory framework to practice: the EU HTA Regulation 2021/2282, AIFA role and interactions with developers: processes, interfaces, expectations

Patrizia Popoli, Walter Marrocco, Anna Ponzianelli, Francesco Damele, Massimo Medaglia

245-248

DOI: https://doi.org/10.33393/grhta.2025.3599
- ePub
- PDF
Optimising pediatric paracetamol and ibuprofen use: a retrospective study with expert evaluation of efficacy, safety, and healthcare costs

Andrea Marcellusi, Angela Ragonese, Antonio D'Avino, Maurizio Taglialatela, Andrea Lo Vecchio

227-233

DOI: https://doi.org/10.33393/grhta.2025.3579
- PDF
- ePub
Economic consequences of the introduction of the JADA® device for the management of postpartum haemorrhage in Italy

Andrea Marcellusi, Giulio Guarnotta, Carlo Tomino

218-226

DOI: https://doi.org/10.33393/grhta.2025.3446
- PDF
- ePub
The economic impact of multimorbidity in Italy: evaluation of direct costs and scenario analysis of patients with type 2 diabetes, heart failure, and chronic kidney disease using real-world data

Valentina Perrone, Claudio Ripellino, Maria Cappuccilli, Melania Leogrande, Andrea Cinti Luciani, Luca Degli Esposti

205-213

DOI: https://doi.org/10.33393/grhta.2025.3509
- PDF
- ePub
RWE in oncology: use of databases to identify molecular subtypes of metastatic breast cancer in Italy

Valentina Perrone, Maria Cappuccilli, Melania Leogrande, Stefania Saragoni, Andrea Cinti Luciani, Sandro Barni, Luca Degli Esposti

198-204

DOI: https://doi.org/10.33393/grhta.2025.3568
- ePub
- PDF
Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism

Ilaria Valentini, Michele Basile, Fabio Vescini, Giorgio Borretta, Iacopo Chiodini, Marco Boniardi, Marina Carotti, Elena Castellano, Cristiana Cipriani, Cristina Eller-Vainicher, Sandro Giannini, Maurizio Iacobone, Antonio Stefano Salcuni, Federica Saponaro, Stefano Spiezia, Annibale Versari, Guido Zavatta, Zuzana Mitrova, Rosella Saulle, Alexia Giovanazzi, Roberto Novizio, Agostino Paoletta, Enrico Papini, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Pietro Giorgio Calò, Filomena Cetani, Luisella Cianferotti, Sabrina Corbetta, Maria Luisa De Rimini, Alberto Falchetti, Stefano Laureti, Bruno Madeo, Claudio Marcocci, Sandro Mazzaferro, Vittorio Miele, Salvatore Minisola, Andrea Palermo, Jessica Pepe, Alfredo Scillitani, Franco Grimaldi, Renato Cozzi, Roberto Attanasio

186-193

DOI: https://doi.org/10.33393/grhta.2025.3531
- PDF
- ePub
Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context

Agostino Fortunato, Eugenio Di Brino, Michele Basile, Debora Antonini, Filippo Rumi

177-185

DOI: https://doi.org/10.33393/grhta.2025.3401
- PDF
- ePub
Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19

Carolina Moreno, Andrea Aiello, Roberto Di Virgilio, Valentina Mazzotta, Andrea Antinori

168-176

DOI: https://doi.org/10.33393/grhta.2025.3403
- PDF
- ePub
Real-World Evidence and Managed Entry Agreements

Silvia Adami, Cosetta Bianchi, Elisa Crovato, Gianluca Trifirò

163-167

DOI: https://doi.org/10.33393/grhta.2025.3563
- PDF
- ePub
C(nn) and compassionate use: two approaches for early access. Proposals for a better management

Alberto Bortolami, Irene Marzona, Paolo Stella, Valentina Acciai, Vito Ladisa, Massimo Medaglia

158-162

DOI: https://doi.org/10.33393/grhta.2025.3464
- PDF
- ePub
Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections

Matteo Scortichini, Alessandro Ruggieri, Agnese Cattaneo, Patrizia Mascagni, Paolo Sciattella

151-157

DOI: https://doi.org/10.33393/grhta.2025.3363
- PDF
- ePub
Time to market evaluation for new chemical entities in Italy: a critical analysis of the period 2018-2024

Alessandro Tedesco, Marzia Bonfanti, PhD, Asia Barugolo, Fulvio Luccini, Patrizia Berto

141-150

DOI: https://doi.org/10.33393/grhta.2025.3422
- PDF
- ePub
Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data

Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini

130-140

DOI: https://doi.org/10.33393/grhta.2025.3397
- PDF
- ePub
Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control

Martina Paoletti, Angela Ragonese, Luca Budassi, Andrea Marcellusi

118-129

DOI: https://doi.org/10.33393/grhta.2025.3341
- PDF
- ePub
Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy

Andrea Marcellusi, Chiara Bini, Laura Fioravanti, Silvia Ripoli, Paolo Morelli

106-117

DOI: https://doi.org/10.33393/grhta.2025.3306
- PDF
- ePub
Regional tools for the governance of prescribing behaviour and pharmaceutical spending: from literature to concrete experiences and prospects for change

Giovanna Scroccaro , Luca Piccoli , Giacomo Vitturi, Maria Cristina Carena, Gianfranco Valenzano

98-105

DOI: https://doi.org/10.33393/grhta.2025.3324
- PDF
- ePub
Management and utilization of the Fund for Innovative Medicines: a multistakeholder qualitative survey on regional and local practices

Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, Andrea Marcellusi

89-97

DOI: https://doi.org/10.33393/grhta.2025.3433
- PDF
- ePub
- HTML
Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)

Matteo Scortichini, Martina Paoletti, Angela Ragonese, Antonio Cuneo, Marco Vignetti, Pier Luigi Zinzani

80-88

DOI: https://doi.org/10.33393/grhta.2025.3365
- PDF
- ePub
- HTML
Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy

Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi

70-79

DOI: https://doi.org/10.33393/grhta.2025.3458
- PDF
- ePub
- HTML
D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine

Maria Giulia Pollice, Luca Degli Esposti, Cataldo Procacci, Salvatore Lenti, Domenica Ancona, Carmela Nappi, Biagio Iacolare, Anna Maria Tesse, Domenico Leuci, Mara Masullo, Domenico Tricarico

61-69

DOI: https://doi.org/10.33393/grhta.2025.3194
- PDF
- ePub
- HTML
Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide

Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini, Emanuela Foglia

49-60

DOI: https://doi.org/10.33393/grhta.2025.3292
- PDF
- ePub
- HTML
Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in Italy

Paolo Sciattella, Matteo Scortichini

34-42

DOI: https://doi.org/10.33393/grhta.2025.3243
- PDF
- ePub
- HTML
Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Andrea Marcellusi, Chiara Bini, Barbara Muzii, Samira Soudani, Alexia Kieffer, Matthieu Beuvelet, Elena Bozzola, Fabio Midulla, Eugenio Baraldi, Paolo Bonanni, Sara Boccalini, Luigi Orfeo

16-28

DOI: https://doi.org/10.33393/grhta.2025.3182
- PDF
- ePub
- HTML
Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)

María Reyes Abad, Carmen Alerany, Luis Ignacio Gonzalez, Olaf Neth, Concepción Payares-Herrera, Carlos Rodríguez-Gallego, Jose Luis Trillo, Kirsten H. Herrmann, Raquel Figueiredo, Alicia Gil

9-15

DOI: https://doi.org/10.33393/grhta.2025.3199
- PDF
- ePub
- HTML

Short Communication

The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicines

Raffaella Cocciolo, Paola Turella, Daniela Pilunni, Pierluigi Navarra

1-6

DOI: https://doi.org/10.33393/grhta.2025.3259
- PDF
- ePub
- HTML